Overview Performance Dividends Fundamentals Peer Group Correlations Pair Trades Institutions Insider Forecasts Options

Performance of NOVO-B Novo Nordisk A/S | 61.3% in 12m

Compare NOVO-B with Indices, Sectors and Commodities ✔ like Oil, Gas, Gold, Yields and Bonds. Who outperforms?

Compare Novo Nordisk A/S with its related Sector/Index XBI

Compare Novo Nordisk A/S with its related Sector/Index XBI

Performance Duell NOVO-B vs XBI

TimeFrame NOVO-B XBI
1 Day -0.46% -0.02%
1 Week 3.36% 4.06%
1 Month 5.23% 8.15%
3 Months 8.06% -0.60%
6 Months 35.5% 32.05%
12 Months 61.3% 8.91%
YTD 31.9% 2.62%
Rel. Perf. 1m -0.06
Rel. Perf. 3m 2.41
Rel. Perf. 6m 0.05
Rel. Perf. 12m 4.01

Is Novo Nordisk A/S a good stock to buy?

Yes, based on ValueRay Fundamental Analyses, Novo Nordisk A/S (CO:NOVO-B) is currently (May 2024) a good stock to buy. It has a ValueRay Fundamental Rating of 87.14 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of NOVO-B as of May 2024 is 1187.55. This means that NOVO-B is currently undervalued and has a potential upside of +30.09% (Margin of Safety).

Is NOVO-B a buy, sell or hold?

Novo Nordisk A/S has no consensus analysts rating. ValueRay therefore judges the recommendation based on the last 12 Month Returns of 61.31%.

In compare to SPDR S&P Biotech, NOVO-B made 52.4% more over the last 12 months. Due to the outperformance, it is recommend to buy NOVO-B.
Values above 0%: NOVO-B is performing better - Values below 0%: NOVO-B is underperforming

Compare NOVO-B with Broad Market Indices

Symbol 1w 1m 6m 12m
US S&P 500 SPY 1.72% 0.23% 17.27% 30.57%
US NASDAQ 100 QQQ 0.87% 0.39% 17.98% 22.23%
US Dow Jones Industrial 30 DIA 2.04% -0.50% 20.42% 38.13%
German DAX 40 DBXD 3.19% 0.05% 17.34% 44.02%
UK FTSE 100 ISFU 1.30% -5.25% 17.34% 46.61%
Shanghai Shenzhen CSI 300 CSI 300 4.35% 0.64% 32.69% 71.16%
Hongkong Hang Seng HSI -1.15% -16.38% 31.31% 68.80%
Japan Nikkei 225 EXX7 2.75% 7.06% 22.55% 47.65%
India NIFTY 50 INDA 1.50% 2.53% 18.75% 33.85%
Brasil Bovespa EWZ 3.83% -0.16% 38.05% 47.56%

NOVO-B Novo Nordisk A/S vs. Sectors

Symbol 1w 1m 6m 12m
Communication Services XLC 2.38% 2.18% 17.25% 22.39%
Consumer Discretionary XLY 4.07% 2.56% 28.03% 39.77%
Consumer Staples XLP 1.78% -2.01% 21.17% 55.52%
Energy XLE 4.10% 6.02% 20.63% 35.45%
Financial XLF 2.14% -1.31% 13.38% 26.56%
Health Care XLV 1.45% -0.07% 20.99% 47.88%
Industrial XLI 3.68% 2.40% 15.22% 30.92%
Materials XLB 3.75% 2.34% 20.29% 40.93%
Real Estate XLRE 1.23% -2.35% 26.02% 49.89%
Technology XLK -0.31% 0.01% 19.20% 20.84%
Utilities XLU 2.04% -9.92% 17.12% 49.13%
Aerospace & Defense XAR 2.96% -2.30% 19.63% 34.36%
Biotech XBI -0.70% -2.92% 3.49% 52.40%
Homebuilder XHB 3.89% -0.15% 3.82% 8.26%
Retail XRT 0.99% -2.60% 10.36% 31.59%

NOVO-B Novo Nordisk A/S vs. Commodities

Symbol 1w 1m 6m 12m
Oil USO 3.71% 11.48% 23.49% 39.39%
Natural Gas UNG -4.03% -20.25% 64.23% 95.09%
Gold GLD 1.94% 5.77% 15.76% 42.29%
Silver SLV -1.28% 0.35% 11.18% 37.24%
Copper CPER -1.68% -6.29% 5.06% 27.93%

Returns of NOVO-B vs. Yields & Bonds

Symbol 1w 1m 6m 12m
iShares 20+ Years Bond TLT 1.84% 0.66% 30.84% 68.48%
iShares High Yield Corp. Bond HYG 3.04% 2.59% 28.75% 50.18%
Does Novo Nordisk A/S outperform its market, is NOVO-B a Sector Leader?
Yes, over the last 12 months Novo Nordisk A/S (NOVO-B) made 61.31%, while its related Sector, the SPDR S&P Biotech (XBI) made 8.91%.
Over the last 3 months NOVO-B made 8.06%, while XBI made -0.60%.
Period NOVO-B XBI S&P 500
1 Month 5.23% 8.15% 5.00%
3 Months 8.06% -0.60% 6.17%
12 Months 61.31% 8.91% 30.74%